# Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females

> **NCT00818155** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** desvenlafaxine succinate SR
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00818155
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00818155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00818155, "Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00818155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*